SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo tackles Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests a combination of two drugs (zanubrutinib and pemetrexed) followed by zanubrutinib alone for people with a type of brain lymphoma that has returned or not responded to prior treatment. The goal is to see how well the treatment shrinks tumors and controls the disea…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated May 26, 2026 12:10 UTC
-
New drug may stop aggressive lymphoma relapse after transplant
Disease control Recruiting nowThis study tests whether the drug acalabrutinib can help prevent relapse in people with very high-risk large B-cell lymphoma after they have received cell therapy (stem cell transplant or CAR T-cells). About 24 adults aged 18-70 will take acalabrutinib as a maintenance treatment.…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:10 UTC
-
New drug duo targets Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. About 26 adults with this rare brain cancer will take part. The main goal is to find the best do…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New drug combo targets brain lymphoma in early trial
Disease control Recruiting nowThis early-phase trial tests the safety of a new drug called glofitamab, given after a pre-treatment with obinutuzumab, for people with central nervous system (CNS) lymphoma. The drugs work by helping the immune system attack cancer cells. The study involves 20 participants and a…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:04 UTC
-
New cell therapy takes on hard-to-treat brain lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a new cell therapy called MB-CART19.1 for people with central nervous system lymphoma (CNSL) that has returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to attack cancer, and is made on-site. The …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
Blood cancer Patients' memory after brain radiation under study
Knowledge-focused Recruiting nowThis study tracks memory and thinking changes in 100 adults with blood cancers (like lymphoma or leukemia) who receive whole brain radiation. Researchers will test cognitive skills over time to understand the treatment's effects on the brain. The goal is to learn more, not to tes…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 12:04 UTC